The Chinese Journal of Clinical Pharmacology 2009;25(4):298-301

doi:10.3969/j.issn.1001-6821.2009.04.003

Study on pharmacokinetics of fluorouracil sustained release implant in the treatment with malignant pleural or peritoneal effusions

Yan-Yan HONG 1 ; Zhen-Dong CHEN ; Ming-Jun ZHANG ; Min YU ; Xiu-Wei WU ; Rui-Ping YE ; Li-Wei LIU ; Yang YANG

Affiliations

+expand

Keywords

fluorouracil sustained release preparations; pharmacokinet-its; malignant pleural effusions; malignant ascites

Country

China

Language

Chinese

Abstract

Objective To investigate the pharmacokinetics of fluoroura-cil (5-Fu) sustained release implant (FSRI) administered intrapleural-ly or intraperitoneally in the patients with malignant pleural effusions or ascites. Methods Twelve patients with moderate or large malignant pleural effusions or ascites were enrolled. FSRI was administered intra-pleurally or intraperitoneally at a fixed dosage of 1500 mg. The pleural or peritoneal effusions and plasma samples were obtained before and after administration. Concentrations of 5-Fu were measured by HPLC. Phar-macokinetic parameters were calculated. Results In the pleural(perito-neal) effusions, 5-Fu concentration was significantly higher than that in plasma (P<0.05 ). Drugs released slowly, and the concentrations in the effusions were still more than the effective concentration at the 15th day.Conclusion When administered intrapleurally or intraperitoneally flu-orouracil sustained release implant had a long elimination and high localconcentrations.